Zheng Ping-Pin, Hop Wim C, Sillevis Smitt Peter A E, van den Bent Martin J, Avezaat Cees J J, Luider Theodorus M, Kros Johan M
Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.
Clin Cancer Res. 2005 Jun 15;11(12):4388-92. doi: 10.1158/1078-0432.CCR-04-2512.
Testing the feasibility of using the serum low-molecular weight caldesmon (l-CaD) level as a serum marker for the presence of glioma.
Within a total of 230 serum samples, the l-CaD level was measured in healthy volunteers (30), patients with gliomas (57), nonglial intracranial tumors (107), and nontumor neurologic diseases (36) by ELISA. The specificity of the assay was monitored by combination of immunoprecipitation and immunoblotting.
The serum level of l-CaD is significantly higher in the group of glioma patients as compared with any of the other groups (P < 0.001). The cutoff value of 45 yields optimal sensitivity and specificity of the assay (91% and 84%, respectively; area under the curve score = 0.91). The specificity of ELISA was confirmed by the immunoprecipitation/immunoblotting control experiments. There were no significant differences in serum l-CaD levels between patients with low- or high-grade gliomas.
The serum l-CaD level as determined by ELISA is a good discriminator between glioma patients versus patients with other intracranial tumors, other neurologic diseases, and healthy people. Prospective studies are required to test the contribution of the assay in making the diagnosis of glioma, or its feasibility for monitoring the tumor during treatment.
检测使用血清低分子量钙调蛋白（l-CaD）水平作为胶质瘤存在的血清标志物的可行性。
通过酶联免疫吸附测定法（ELISA）在总共230份血清样本中测量健康志愿者（30例）、胶质瘤患者（57例）、非神经胶质颅内肿瘤患者（107例）和非肿瘤性神经疾病患者（36例）的l-CaD水平。通过免疫沉淀和免疫印迹相结合的方法监测该检测方法的特异性。
与其他任何组相比，胶质瘤患者组的血清l-CaD水平显著更高（P < 0.001）。45的临界值产生了该检测方法的最佳敏感性和特异性（分别为91%和84%；曲线下面积得分 = 0.91）。免疫沉淀/免疫印迹对照实验证实了ELISA的特异性。低级别或高级别胶质瘤患者之间的血清l-CaD水平无显著差异。
通过ELISA测定的血清l-CaD水平是区分胶质瘤患者与其他颅内肿瘤患者、其他神经疾病患者和健康人的良好指标。需要进行前瞻性研究来测试该检测方法在胶质瘤诊断中的作用，或其在治疗期间监测肿瘤的可行性。
